These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 37571885)

  • 41. Downregulation of PSAT1 inhibits cell proliferation and migration in uterine corpus endometrial carcinoma.
    Wang M; Yue S; Yang Z
    Sci Rep; 2023 Mar; 13(1):4081. PubMed ID: 36906716
    [TBL] [Abstract][Full Text] [Related]  

  • 42.
    Holst F; Werner HMJ; Mjøs S; Hoivik EA; Kusonmano K; Wik E; Berg A; Birkeland E; Gibson WJ; Halle MK; Trovik J; Cherniack AD; Kalland KH; Mills GB; Singer CF; Krakstad C; Beroukhim R; Salvesen HB
    Clin Cancer Res; 2019 Jan; 25(1):334-345. PubMed ID: 30442683
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Inflammation-Related LncRNAs Signature for Prognosis and Immune Response Evaluation in Uterine Corpus Endometrial Carcinoma.
    Gu H; Song J; Chen Y; Wang Y; Tan X; Zhao H
    Front Oncol; 2022; 12():923641. PubMed ID: 35719911
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Signal transducer and activator of transcription family is a prognostic marker associated with immune infiltration in endometrial cancer.
    Zhou XY; Dai HY; Zhang H; Zhu JL; Hu H
    J Clin Lab Anal; 2022 Apr; 36(4):e24315. PubMed ID: 35244291
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Gene Signatures and Prognostic Value of m6A RNA Methylation Regulators in Uterine Corpus Endometrial Carcinoma.
    Feng Y; Yao C; Shen J; Zhou J
    Discov Med; 2021; 31(164):111-120. PubMed ID: 35188885
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Construction of prediction model for prognosis of uterine corpus endometrial carcinoma based on pyroptosis gene.
    Zhang C; Bai J; Yang Y; Wang X; Liu W; Hou S; Ai Z; Xia Q; Shao L
    Clin Transl Oncol; 2023 May; 25(5):1413-1424. PubMed ID: 36520385
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Expression of Pyroptosis-Related Gene May Influence the Occurrence, Development, and Prognosis of Uterine Corpus Endometrial Carcinoma.
    Huang X; Li Y; Li J; Yang X; Xiao J; Xu F
    Front Oncol; 2022; 12():885114. PubMed ID: 35574367
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A TP53-based immune prognostic model for muscle-invasive bladder cancer.
    Li H; Lu H; Cui W; Huang Y; Jin X
    Aging (Albany NY); 2020 Dec; 13(2):1929-1946. PubMed ID: 33323544
    [TBL] [Abstract][Full Text] [Related]  

  • 49. PPP1R14B is a diagnostic prognostic marker in patients with uterine corpus endometrial carcinoma.
    He K; Wang T; Huang X; Yang Z; Wang Z; Zhang S; Sui X; Jiang J; Zhao L
    J Cell Mol Med; 2023 Mar; 27(6):846-863. PubMed ID: 36824011
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A novel cuproptosis-related gene signature for overall survival prediction in uterine corpus endometrial carcinoma (UCEC).
    Lin S; Xu Y; Liu B; Zheng L; Cao C; Wu P; Ding W; Ren F
    Heliyon; 2023 Apr; 9(4):e14613. PubMed ID: 37035374
    [TBL] [Abstract][Full Text] [Related]  

  • 51. SPC25 Functions as a Prognostic-Related Biomarker, and Its High Expression Correlates with Tumor Immune Infiltration and UCEC Progression.
    Liao LX; Zhang M; Xu X; Zhang S; Guo YZ
    Front Biosci (Landmark Ed); 2024 Feb; 29(2):69. PubMed ID: 38420826
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinicopathological role of Cyclin A2 in uterine corpus endometrial carcinoma: Integration of tissue microarrays and ScRNA-Seq.
    Mo WJ; Liang ZQ; Huang JZ; Huang ZG; Zhi ZF; Chen JH; Chen G; Zeng JJ; Feng ZB
    Int J Biol Markers; 2024 Jun; 39(2):168-183. PubMed ID: 38646803
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Construction of Oxidative Stress-Related Genes Risk Model Predicts the Prognosis of Uterine Corpus Endometrial Cancer Patients.
    Liu Q; Yu M; Zhang T
    Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428665
    [TBL] [Abstract][Full Text] [Related]  

  • 54. ARID1A Downregulation Predicts High PD-L1 Expression and Worse Clinical Outcome in Patients With Gallbladder Cancer.
    Nan L; Wang C; Wang J; Zhang S; Bo X; Wang Y; Liu H
    Front Oncol; 2022; 12():787897. PubMed ID: 35198440
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comprehensive bioinformatic analyses of lncRNA-mediated ceRNA network for uterine corpus endometrial carcinoma.
    Cai Y; Cui J; Wang Z; Wu H
    Transl Cancer Res; 2022 Jul; 11(7):1994-2012. PubMed ID: 35966302
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Identification and Validation of Cuproptosis-Related Prognostic Signature and Associated Regulatory Axis in Uterine Corpus Endometrial Carcinoma.
    Chen Y
    Front Genet; 2022; 13():912037. PubMed ID: 35937995
    [No Abstract]   [Full Text] [Related]  

  • 57. Identification and validation of oxeiptosis-associated lncRNAs and prognosis-related signature genes to predict the immune status in uterine corpus endometrial carcinoma.
    Niu L; Wu Z
    Aging (Albany NY); 2023 May; 15(10):4236-4252. PubMed ID: 37211398
    [TBL] [Abstract][Full Text] [Related]  

  • 58. KNL1 is a prognostic and diagnostic biomarker related to immune infiltration in patients with uterine corpus endometrial carcinoma.
    He K; Li J; Huang X; Zhao W; Wang K; Wang T; Chen J; Wang Z; Yi J; Zhao S; Zhao L
    Front Oncol; 2023; 13():1090779. PubMed ID: 36776306
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The landscape and prognostic value of immune characteristics in uterine corpus endometrial cancer.
    Liu W; Sun L; Zhang J; Song W; Li M; Wang H
    Biosci Rep; 2021 Apr; 41(4):. PubMed ID: 33782686
    [TBL] [Abstract][Full Text] [Related]  

  • 60. m
    Fang F; Wang P; Huang H; Ye M; Liu X; Li Q
    BMC Cancer; 2022 Dec; 22(1):1364. PubMed ID: 36581816
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.